Novartis to Pay $150M for Monte Rosa Glue Drug in the Clinic for Immunology Indications

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Novartis is getting global rights to a Monte Rosa Therapeutic molecular glue degrader drug in early clinical testing as a potential treatment for autoimmune disorders. The deal comes months after the pharma giant landed rights to an Arvinas targeted protein degrader for cancer.

The post Novartis to Pay $150M for Monte Rosa Glue Drug in the Clinic for Immunology Indications appeared first on MedCity News.

Leave a Replay

Sign up for our Newsletter

Contact Us